{
  "id": 20869128,
  "title": "Two days in cell-free, three days in CHO: antibody sequence to data with Biointron’s RushDATA™",
  "url": "https://urgent.news/2026/11/19/two-days-in-cell-free-three-days-in-cho-antibody-sequence-to-data",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-19T08:00:00.000Z",
  "source": {
    "name": "Labiotech",
    "slug": "labiotech",
    "url": "https://www.labiotech.eu/partner/ai-antibody-design-validation/"
  },
  "original_language": "en",
  "account": null,
  "summary": "A few years ago, a drug discovery team could only rank a handful of candidates at a time. Today a generative model can propose several thousand sequences in hours. The design step, once the slowest part of antibody discovery, has become one of the fastest. Validation is where the calendar time now sits. Expression, binding […] The post Two days in cell-free, three days in CHO: antibody sequence…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}